CLDX Celldex Therapeutics Inc

Price (delayed)

$27.84

Market cap

$1.3B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.71

Enterprise value

$1.28B

Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which ...

Highlights
CLDX's quick ratio has surged by 150% year-on-year and by 6% since the previous quarter
The debt has decreased by 16% YoY and by 13% QoQ
Celldex Therapeutics's equity has soared by 105% YoY but it has decreased by 5% from the previous quarter
CLDX's EPS is up by 8% YoY but it is down by 4.3% from the previous quarter
The company's gross profit fell by 23% YoY and by 11% QoQ
Celldex Therapeutics's revenue has decreased by 23% YoY and by 11% from the previous quarter

Key stats

What are the main financial stats of CLDX
Market
Shares outstanding
46.75M
Market cap
$1.3B
Enterprise value
$1.28B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.27
Price to sales (P/S)
314.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
308.86
Earnings
Revenue
$4.14M
EBIT
-$77.25M
EBITDA
-$74.15M
Free cash flow
-$68.61M
Per share
EPS
-$1.71
Free cash flow per share
-$1.47
Book value per share
$8.52
Revenue per share
$0.09
TBVPS
$8.49
Balance sheet
Total assets
$424.04M
Total liabilities
$25.94M
Debt
$2.64M
Equity
$398.1M
Working capital
$376.14M
Liquidity
Debt to equity
0.01
Current ratio
26.83
Quick ratio
26.15
Net debt/EBITDA
0.31
Margins
EBITDA margin
-1,790.5%
Gross margin
100%
Net margin
-1,860%
Operating margin
-1,938.8%
Efficiency
Return on assets
-20.1%
Return on equity
-21.4%
Return on invested capital
-25.9%
Return on capital employed
-18.9%
Return on sales
-1,865.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CLDX stock price

How has the Celldex Therapeutics stock price performed over time
Intraday
-2.96%
1 week
12.39%
1 month
1.16%
1 year
-21.29%
YTD
-27.95%
QTD
-18.26%

Financial performance

How have Celldex Therapeutics's revenue and profit performed over time
Revenue
$4.14M
Gross profit
$4.14M
Operating income
-$80.29M
Net income
-$77.02M
Gross margin
100%
Net margin
-1,860%
The net margin has shrunk by 57% YoY and by 23% QoQ
CLDX's operating margin is down by 47% year-on-year and by 24% since the previous quarter
The company's gross profit fell by 23% YoY and by 11% QoQ
Celldex Therapeutics's revenue has decreased by 23% YoY and by 11% from the previous quarter

Growth

What is Celldex Therapeutics's growth rate over time

Valuation

What is Celldex Therapeutics stock price valuation
P/E
N/A
P/B
3.27
P/S
314.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
308.86
CLDX's EPS is up by 8% YoY but it is down by 4.3% from the previous quarter
Celldex Therapeutics's equity has soared by 105% YoY but it has decreased by 5% from the previous quarter
The P/B is 60% higher than the 5-year quarterly average of 2.1 but 36% lower than the last 4 quarters average of 5.3
Celldex Therapeutics's revenue has decreased by 23% YoY and by 11% from the previous quarter
CLDX's price to sales (P/S) is 8% higher than its last 4 quarters average of 299.3

Efficiency

How efficient is Celldex Therapeutics business performance
CLDX's ROS has plunged by 55% YoY and by 23% from the previous quarter
Celldex Therapeutics's ROIC has increased by 42% YoY and by 14% from the previous quarter
The ROE has grown by 27% YoY and by 7% from the previous quarter
The ROA is up by 23% YoY and by 5% QoQ

Dividends

What is CLDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CLDX.

Financial health

How did Celldex Therapeutics financials performed over time
The current ratio has soared by 151% YoY and by 8% from the previous quarter
CLDX's quick ratio has surged by 150% year-on-year and by 6% since the previous quarter
The debt is 99% lower than the equity
Celldex Therapeutics's equity has soared by 105% YoY but it has decreased by 5% from the previous quarter
CLDX's debt to equity has dropped by 50% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.